Insider Selling: Equillium (NASDAQ:EQ) COO Sells $31,897.36 in Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 23,804 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $1.34, for a total transaction of $31,897.36. Following the transaction, the chief operating officer directly owned 103,344 shares in the company, valued at approximately $138,480.96. This represents a 18.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Christine Zedelmayer also recently made the following trade(s):

• On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The stock was sold at an average price of $1.31, for a total transaction of $15,589.00.
• On Tuesday, November 25th, Christine Zedelmayer sold 8,098 shares of Equillium stock. The shares were sold at an average price of $0.95, for a total transaction of $7,693.10.

Equillium Trading Down 9.1%

Shares of NASDAQ:EQ opened at $1.10 on Thursday. The stock has a market capitalization of $66.98 million, a P/E ratio of -1.77 and a beta of 1.92. The stock’s 50-day moving average price is $1.15 and its 200-day moving average price is $1.00. Equillium, Inc. has a 12-month low of $0.27 and a 12-month high of $2.35.

Equillium (NASDAQ:EQ) last issued its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.08. As a group, research analysts predict that Equillium, Inc. will post 0.14 EPS for the current year.

Institutional Trading of Equillium

Large investors have recently bought and sold shares of the company. ADAR1 Capital Management LLC bought a new position in shares of Equillium in the 3rd quarter worth approximately $7,951,000. Woodline Partners LP purchased a new stake in Equillium in the third quarter worth $5,018,000. Vanguard Group Inc. raised its holdings in Equillium by 59.4% in the third quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock worth $1,879,000 after purchasing an additional 489,855 shares in the last quarter. Cantor Fitzgerald L. P. purchased a new position in Equillium during the third quarter valued at $608,000. Finally, Aberdeen Group plc purchased a new position in Equillium during the third quarter valued at $543,000. 27.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Wall Street Zen upgraded shares of Equillium from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a report on Monday. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $1.00.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.